Ocugen (OCGN) Stock Analysis & Winston Score

Ocugen is a small biotechnology company focused on developing treatments for eye diseases and gene therapies. Its main programs target inherited retinal diseases — conditions where people slowly lose their vision due to genetic defects — as well as modifier gene therapy platforms it calls OCU400 and OCU200. The company's customers would eventually be patients and healthcare providers, though most of its drugs are still in clinical trials and not yet approved for sale. Ocugen makes almost no product revenue today and funds itself primarily through stock offerings and partnerships. It operates mainly in the United States, with some international collaboration history, including a past COVID-19 vaccine partnership in India. With a market cap around $400 million and a deeply negative operating margin, the company is burning cash while it runs clinical trials. The key risk is that it must successfully advance its gene therapy candidates through expensive FDA approval processes before its cash runs out, which is a common and serious challenge for pre-revenue biotech firms.